Switching to Insulin Glargine 300 U/mL (Gla-300) after Failure of Advanced Insulin Therapy (IT) with Other Basal Insulins (BI) in Patients (Pts) with Type 2 Diabetes (T2DM) Improved Glycemic Control

The prospective observational Toujeo-Neo study investigated effects of switching to Gla-300 in 1,217 pts with T2DM, uncontrolled (A 1c 7.5-10%) on another BI plus oral therapy plus prandial IT (BOTplus), or basal-bolus therapy (BBT) in daily clinical practice in Germany. Primary endpoint (EP) was duration of response (fasting plasma glucose (FPG) ≤110 mg/dL or A 1c ≤ predefined individual target). Secondary EPs included changes in A 1c , FPG, body weight (BW) and insulin doses, hypoglycemia incidences and safety. Here we report on pts with 12 months results available (n=798). Pts baseline characteristics, efficacy and hypoglycemia EPs are shown in Table 1. Main prev. BI was insulin glargine 100 U/mL (41.2%), most common oral therapy was metformin ± DPP-4 inhibitor (52.9%). At 12 months, proportion of pts at A 1c target in BBT (n=446) was highest in pts previously on NPH insulin (n=84; 45.2%). Pts on BOTplus (n=82) achieved a greater A 1c reduction (-0.71% vs. -0.53%) and higher A 1c (48.8 vs. 38.4%) and FPG (22.0 vs. 17.7%) response rates than pts on BBT. Hypoglycemia rates were low and did not change significantly despite A 1c reduction. BW remained stable. In conclusion, switching the BI in BOTplus or BBT to Gla-300 allowed uncontrolled T2DM pts to reduce their A 1c by 0.56% w/o impact on hypoglycemia risk and minor BI dose changes. Disclosure S. Pscherer: Advisory Panel; Self; Sanofi-Aventis Deutschland GmbH. A. Fritsche: Advisory Panel; Self; Sanofi-Aventis Deutschland GmbH, Novo Nordisk A/S, Eli Lilly and Company, Boehringer Ingelheim GmbH. H. Anderten: Advisory Panel; Self; Sanofi-Aventis Deutschland GmbH, Merck Sharp & Dohme Corp.. Speaker9s Bureau; Self; Sanofi-Aventis Deutschland GmbH, Merck Sharp & Dohme Corp., Eli Lilly and Company, Boehringer Ingelheim GmbH, Pfizer Inc., AstraZeneca, GlaxoSmithKline plc., Novartis AG, Novo Nordisk A/S, Takeda. K. Pegelow: Employee; Self; Sanofi-Aventis Deutschland GmbH. J. Seufert: Speaker9s Bureau; Self; AstraZeneca, Berlin-Chemie AG, Boehringer Ingelheim GmbH. Research Support; Self; Boehringer Ingelheim GmbH. Advisory Panel; Self; Boehringer Ingelheim GmbH, GI Dynamics Inc.. Research Support; Self; GI Dynamics Inc., GlaxoSmithKline plc., Intarcia Therapeutics, Inc., Ipsen Biopharmaceuticals, Inc., Janssen Pharmaceuticals, Inc.. Speaker9s Bureau; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Speaker9s Bureau; Self; Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation. Research Support; Self; Novartis Pharmaceuticals Corporation. Advisory Panel; Self; Novo Nordisk A/S. Speaker9s Bureau; Self; Novo Nordisk A/S. Research Support; Self; Novo Nordisk A/S. Speaker9s Bureau; Self; Sanofi-Aventis Deutschland GmbH. Advisory Panel; Self; Sanofi-Aventis Deutschland GmbH. Research Support; Self; Sanofi-Aventis Deutschland GmbH. Advisory Panel; Self; Sanofi. Research Support; Self; Ypsomed AG. M. Pfohl: Advisory Panel; Self; Eli Lilly and Company, Novo Nordisk A/S, Sanofi. Speaker9s Bureau; Self; Sanofi.